Fig 1: Associations between APOBEC3B mRNA expression and (A) purity, B-cells, CD8+ T-cells, CD4+ T-cells, (B) macrophages, neutrophils, dendritic cells and (C) CD274 mRNA. (D) Schematic representation demonstrating the association between APOBEC3B, tumor infiltrating lymphocytes and prognosis for breast cancer. ***P<0.05. APOBEC3B, apolipoprotein B mRNA editing enzyme catalytic subunit 3B.
Fig 2: Representative immunohistochemical staining microphotographs of E6 and APOBEC3B expression in UTUC. (a, b) The low expression of APOBEC3B, respectively. (c, d) The high expression of APOBEC3B, respectively. (e, f) Negative expression of E6, respectively. (g, h) The positive expression of E6, respectively.
Fig 3: Kaplan-Meier survival analysis of HPV E6 and APOBEC3B with DFS of patients with UTUC. (a) Effect of the APOBEC3B expression on DFS; (b) effect of the HPV E6 expression on DFS; (c) effect of the APOBEC3B and HPV E6 double-positive expression on DFS; (d) effect of the different expression patterns of APOBEC3B and HPV E6 expression on DFS.
Fig 4: APOBEC3B expression is associated with copy number alterations.(A) Genome-wide CGH array representing cumulative copy number gain or loss for all chromosomes in adrenocortical carcinoma samples were dichotomized by the median gene expression level of APOBEC3B in the tumor samples. Red indicates the copy number loss while blue represents the copy number gain in a given chromosome. The columns represent each chromosome. Overall patient survival dichotomized based on the median gene expression level of APOBEC3B from two publicly available datasets; E-TABM-311 (B), GSE19776, (C) our cohort, (D) and the TCGA adrenocortical cancer data (E).
Fig 5: APOBEC3B mRNA expression differences between primary breast tumors and paired metastases.(A) APOBEC3B mRNA expression in primary breast tumors versus paired loco-regional and distant metastases. (B) APOBEC3B mRNA expression in primary breast tumors versus paired metastases, subdivided per location of metastasis (ovary (N = 4); liver (N = 6); bone (N = 4); brain (N = 14); lung (N = 5) and gastro-intestinal tract (N = 3). (C) APOBEC3B mRNA expression in ESR1-positive primary breast tumors versus paired distant and loco-regional metastases. (D) APOBEC3B mRNA expression in ESR1-negative primary breast tumors versus paired distant and loco-regional metastases. P-values obtained by paired Wilcoxon Signed Ranks test (2-tailed).
Supplier Page from Abcam for Anti-APOBEC3B antibody - N-terminal